Publication: Therapy of endocrine disease: Amylin and calcitonin – physiology and pharmacology
Therapy of endocrine disease: Amylin and calcitonin – physiology and pharmacology
Date
Date
Date
Citations
Mathiesen, D. S., Lund, A., Holst, J. J., Knop, F. K., Lutz, T. A., & Bagger, J. I. (2022). Therapy of endocrine disease: Amylin and calcitonin – physiology and pharmacology. European Journal of Endocrinology, 186(6), R93–R111. https://doi.org/10.1530/eje-21-1261
Abstract
Abstract
Abstract
Type 2 diabetes is a common manifestation of metabolic dysfunction due to obesity and constitutes a major burden for modern health care systems, in concert with the alarming rise in obesity worldwide. In recent years, several successful pharmacotherapies improving glucose metabolism have emerged and some of these also promote weight loss, thus, ameliorating insulin resistance. However, the progressive nature of type 2 diabetes is not halted by these new anti-diabetic pharmacotherapies. Therefore, novel therapies promoting weight loss
Metrics
Downloads
Views
Additional indexing
Creators (Authors)
- Mathiesen, David S
- Lund, Asger
- Holst, Jens J
- Knop, Filip K
- Bagger, Jonatan I
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Page end
Page end
Page end
Item Type
Item Type
Item Type
In collections
Keywords
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Metrics
Downloads
Views
Citations
Mathiesen, D. S., Lund, A., Holst, J. J., Knop, F. K., Lutz, T. A., & Bagger, J. I. (2022). Therapy of endocrine disease: Amylin and calcitonin – physiology and pharmacology. European Journal of Endocrinology, 186(6), R93–R111. https://doi.org/10.1530/eje-21-1261
